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Abstract
Objective:  To  evaluate  if  the  cancer  registry  database  can  be  used  to  monitor  treatment  effec-
tiveness using  nivolumab  treatment  of  non-small  cell  lung  cancer  (NSCLC)  as  an  example.
Method:  An  observational  inception  cohort  was  used,  where  all  registered  cases  of  NSCLC  with
authorisation  to  initiate  treatment  with  nivolumab  were  monitored  retrospectively  to  evaluate
disease  characteristics  and  response  to  prior  treatments.  Current  exposure  to  nivolumab  was
prospectively  characterised  and  treatment  outcomes  classified  based  on  the  clinical  information
registered  in  the  patient  medical  record.  The  main  outcome  measure  used  to  assess  treatment
effectiveness  was  overall  survival  (OS).  Secondary  outcomes  considered  were  progression  free
survival (PFS)  as  a  measure  of  effectiveness  and  occurrence  of  Adverse  Drug  Reaction  (ADRs)  as
a measure  of  safety.  Data  were  analysed  using  SPSS,  version  24.
Results:  A  total  of  115  patients  received  treatment  with  nivolumab  for  NSCLC,  between  Novem-
ber 1st  2015  and  July  31st  2016,  and  were  registered  in  the  database.  The  majority  were
non-squamous  type  (n  =  107).  The  median  OS  was  11.4  months  {CI95%:  11.1--11.7},  with  a  1-year
survival of  44%,  in  line  with  clinical  trial  data.  Median  PFS  was  5.4  months  {CI95%:  2.8--7.9}.
Treatment  was  discontinued  in  82  cases,  most  frequently  due  to  disease  progression.  There
were 38  cases  of  ADRs  documented  in  the  patient  medical  chart,  21  of  which  led  to  treatment
discontinuation.Abbreviations: OS, overall survival; PFS, progression-free survival; ADRs, adverse drug reactions.
∗ Corresponding author.
E-mail address: facosta@ipolisboa.min-saude.pt (F.A. Costa).
https://doi.org/10.1016/j.pulmoe.2018.05.007
2531-0437/© 2018 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
4  F.A.  Costa  et  al.
Conclusion:  The  analysed  data  suggest  that  the  cancer  registry  is  a  powerful  tool  to  monitor
treatment  effectiveness,  although  considerable  investment  is  needed  to  improve  the  medical
culture of  recording  treatment  exposure,  particularly  documentation  of  ADRs.
© 2018  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an

























































































Upper  lobe,  lung;  C34.2  Middle  lobe,  lung;  C34.3  Lower  lobe,ntroduction
ung  cancer  is  one  of  the  leading  causes  of  mortality  in
ortugal  and  worldwide.1 The  visible  improvements  in  sur-
ival  achieved  during  the  last  decade  are  likely  to  be  a
esult  of  the  progressive  increase  in  early  detection  of  the
isease.  The  effectiveness  of  the  smoking  ban  legislation
mplemented  may  have  had  a  role,  although  the  impact  has
ot  yet  been  clearly  identified.2
Apart  from  surgery,  treatments  are  mainly  developed
o  increase  length  of  survival  but  very  few  lead  to  cure.
onetheless,  the  search  for  effective  treatments  remains
 hope  for  all  and  is  of  particular  interest  given  the  ris-
ng  costs  of  marketed  cancer  treatments.3 The  highest
roportion  of  the  costs  for  the  Portuguese  Health  Care  Sys-
em  constantly  correspond  to  the  therapeutic  groups  used
n  cancer  treatment,  including  biological,  immunomodula-
ory  and  cytotoxic  ones.4 The  aforementioned  treatment
elated  costs  are  constantly  rising  and  immunotherapy  is
ot  only  an  important  factor  in  this  trend  but  also  an
rea  where  patient  access  is  sometimes  delayed  by  the
tandard  procedures  implemented.  Ensuring  patient’s  early
ccess  to  medicines  has  long  been  a  subject  of  concern  for
he  World  Health  Organisation  (WHO)  and  for  all  govern-
ents.
Several  mechanisms  exist  to  favour  early  access,  such
s  the  use  of  special  utilisation  authorisations  (SUA).  These
re  normally  used  when  the  medicines  are  still  under  eco-
omic  evaluation  and  before  negotiations  are  finalised.
daptive  pathways  are  a  common  process  through  which
atients  in  Portugal  can  get  access  to  medicines  ahead  of
ull  market  authorisation,5 namely  the  early  access  pro-
ram  that  was  recently  used  for  Nivolumab.  Nivolumab  is
n  immunotherapy  drug  that  modulates  the  programmed
eath  1  (PD-1)  pathway.  The  binding  of  the  ligands  PD-
1  (prevalent  in  NSCLC)  and  PD-L2,  expressed  by  tumour
ells,  to  their  receptor  PD-1,  expressed  by  activated  T  cells,
eads  to  a  downregulation  in  the  immune  response,  favour-
ng  tumour  cell  survival.  Nivolumab  is  an  antibody  against
he  PD-1  immune-checkpoint-inhibitor,  which  by  disrupting
he  PD-1  mediated  signalling,  promotes  a  normal  immune
esponse  against  tumour  cells.  Nivolumab  was  approved
n  the  19th  June  2015  by  the  European  Medicines  Agency
EMA)  following  documentation  of  improvement  in  OS  in
linical  trials  in  advanced  NSCLC  patients.6,7 The  inclusion
riteria  for  the  early  access  program  were:  stage  IIIB  or
V  NSCLC  who  had  progressed  on  previous  chemotherapy
reatment;  poor  expected  outcome  with  available  treat-





These  adaptive  mechanisms  were  set  up  to  create  the
nvironment  for  the  different  stakeholders  involved  to  make
nformed  decisions  on  innovative  medicines.  However,  for
hese  conversations  to  be  meaningful,  real  world  data  must
e  available  and  objectively  monitored.  The  most  common
ources  of  data  for  effectiveness  studies  are  population
ased  registries.  In  Portugal,  until  July  2017,  there  were
our  regional  cancer  registries  South,  North,  Centre  and
zores  Islands  and  recently  the  creation  of  a  single  national
egistry  has  been  approved.8 Currently,  the  ROR-Sul,  the
ancer  registry  for  Southern  Portugal  and  Madeira  Islands,
as  a  thorough  collection  of  data  including  patient  identi-
cation,  cancer  diagnosis,  tumour  characteristics,  detailed
ines  of  treatment  and  patient  vital  status.  In  most  insti-
utions,  all  clinical  and  medical  data  is  entered  into  the
OR-Sul  database.
Given  the  political  and  science-based  context  high-
ighted,  we  suggested  that  the  cancer  registry  traditionally
sed  to  monitor  disease  incidence  and  survival,  could  also
e  used  to  monitor  response  to  treatment.
ethods
n  observational  inception  cohort  was  used,  where  all  reg-
stered  cases  of  lung  cancer  with  authorisation  to  initiate
reatment  with  nivolumab  in  the  early  access  programme
hat  took  place  from  November  1st  2015  to  July  31st  2016
ere  monitored  retrospectively,  retrieving  disease  charac-
eristics  and  type  and  response  to  prior  treatment;  and  also
rospectively  to  characterise  exposure  to  nivolumab  and
reatment  outcomes.
Data  sources:  The  Portuguese  Drug  Regulatory  Agency,
NFARMED  (Autoridade  Nacional  do  Medicamento  e  Produtos
e  Saúde,  I.P.)  has  a database  of  SUA  granted  for  nivolumab
n  the  context  of  the  early  access  programme,  which  was
sed  to  ascertain  the  theoretical  study  population.  The  ROR-
ul  database  was  then  used  to  extract  these  cases  which
omprised  all  granted  SUA  that  were  treated  according  to
he  regulator’s  instructions.
Eligibility  criteria  were  those  matching  the  characteris-
ics  defined  by  the  Regulatory  Agency  for  early  access  to
edication,  i.e.  patients  with  a  histologically  confirmed
iagnosis  of  non-small  cell  lung  cancer,  locally  advanced
r  metastatic.  Cases  were  selected  based  on  the  following
opographic  codes,  using  the  10th  International  Classifica-
ion  of  Disease  for  Oncology9:  C34.0  Main  bronchus;  C34.1ung;  C34.8  Overlapping  lesion  of  lung;  C34.9  Lung,  NOS.  No
dditional  criteria  were  defined  as  we  intended  to  study


















































The  cancer  registry  as  an  ally  in  monitoring  treatment  effec
characteristics  of  the  sample  extracted  are  presented  in  the
results  section.
Therapeutic  response  was  classified  according  to  the
RECIST  criteria,10 based  on  the  information  available  on  the
medical  records  and  clinical  files.
The  main  outcome  measure  used  to  evaluate  treatment
effectiveness  was  OS.  To  estimate  OS,  the  period  considered
was  from  the  day  of  treatment  initiation  with  Nivolumab
until  death  from  any  cause.
PFS  was  considered  a  secondary  outcome  to  evaluate
treatment  effectiveness.  To  estimate  PFS,  the  period  con-
sidered  was  also  from  the  day  of  treatment  initiation  with
Nivolumab  until  disease  progression.  Clinical  and  imagio-
logical  progressions  were  both  considered.  Other  outcome
measures  of  interest  considered  were  response  to  treatment
and  ADRs  documented  in  the  medical  record.
Statistical  analysis:  Data  were  stored  in  the  ROR-Sul  can-
cer  registry  database,  which  was  then  extracted  to  Excel  and
subsequently  analysed  using  SPSS  version  24.0  (IBM  statis-
tics).  Analysis  focused  on  the  univariate  characterisation  of
study  subjects,  disease  and  treatment  characteristics.  Sub-
analysis  focused  on  different  subgroups,  such  as  stage  of
disease  at  treatment  initiation  and  histology  (squamous  ver-
sus  non-squamous).  Survival  analysis  was  used  to  ascertain
the  time  granted  by  submitting  the  patient  to  therapy,  mea-
suring  the  time  from  the  day  of  starting  treatment  with
Nivolumab  until  the  event  (death  or  disease  progression,
respectively  for  OS  and  PFS).  One-year  survival  with  95%  CI
was  used  for  comparison  with  published  clinical  trial  data.6,7
The  primary  reference  considered  focuses  on  non-squamous
carcinomas,6 and  as  such  the  analysis  was  subsequently
restricted  to  such  cases  for  the  purposes  of  comparison.
Results
Sample  characteristics
A  total  of  225  SUA  were  granted  by  INFARMED,  from  a  max-
imal  of  250  initially  established.  These  225  SUE  were  given
to  217  patients  in  32  different  institutions,  both  private
and  public,  throughout  the  country.  The  average  time  from
submission  of  request  by  the  institutions’  Pharmacy  and
Therapeutics  Committee  until  decision  by  the  regulator  was
6.5  ±  5.1  days.
The  majority  of  these  cases  were  registered  in  ROR-Sul
database  (n  =  115;  53.0%),  although  most  SUAs  (84.3%)  which
enabled  analysis  of  treatment  effectiveness  originated  from
the  South  region  of  Portugal.
Most  cases  were  male  patients  (n  =  73;  63.5%),  with  a
median  age  at  diagnosis  of  62  years,  with  significant  differ-
ence  between  genders  [male  64.0,  female  58.5  (p  =  0.017)].
Most  cases  were  stage  IV  NSCLC  at  diagnosis  (n  =  63;  54.8%).
The  majority  were  adenocarcinomas  (n  =  104;  90.4%),  and  49
(42.6%)  were  confined  to  the  upper  lobe  of  the  lung.
Prior  to  treatment  with  nivolumab,  51.3%  of  patients  had
been  treated  with  radiotherapy  (n  =  59),  31.3%  with  surgery
(n  =  36)  and  100%  with  chemotherapy  (n  =  115).  Most  patients
were  treated  with  two  (n  =  41;  35.6%),  three  or  more  (n  =  39;
33.9%)  prior  lines  of  chemotherapy  and  the  remaining  had
received  only  one  line  of  treatment  (n  =  34;  29.6%).  In  98






ancer.  As  nivolumab  is  only  indicated  for  metastatic  or
ocally  advanced  disease,  the  median  time  until  treatment
nitiation  was  determined  differently,  according  to  the  stage
t  diagnosis.  For  stages  IIIB  and  IV,  the  date  of  diagnosis  was
sed  in  this  calculation;  for  stages  I,  II  and  IIIA,  the  date  used
as  that  of  recurrence  and/or  progression  to  stages  IIIB  or  IV.
ence,  the  median  time  from  diagnosis  of  advanced  disease
o  initiation  of  treatment  with  nivolumab  was  1.2  years  ±  1.5
CI95%: 27  days--7.6  years}.
Median  duration  of  treatment  with  nivolumab  was
.6  ±  4.5  months,  and  33  patients  (28.7%)  were  still  under-
oing  treatment  at  the  time  of  database  closure  (May  31st
017).  The  dose  administered  at  treatment  initiation  ranged
rom  100  to  351  mg  (M  =  198.8  ±  44  mg)  and  was  adminis-
ered  every  15  days,  as  approved,  in  93%  of  cases.  The
ompleteness  of  the  registry  for  these  two  treatment  varia-
les  (not  mandatory  in  the  registry)  were  respectively  94.8%
nd  93.0%.
econdary  outcomes
f  the  82  patients  who  stopped  treatment,  in  76  (92.7%)
he  reason  for  treatment  withdrawal  was  documented  in  the
edical  record.  Most  patients  discontinued  treatment  due
o  disease  progression,  although  a  high  proportion  did  so
s  a  result  of  adverse  drug  reactions.  A  total  of  38  adverse
rug  reactions  were  documented,  among  which  20  led  to
reatment  discontinuation  (Table  1).
Response  to  treatment  with  nivolumab  was  evaluated  in
ll  patients:  44  (38.3%)  had  disease  progression,  40  (34.8%)
table  disease  (34.8%),  18  partial  response  and  one  com-
lete  response.  It  was  not  possible  to  determine  response  to
reatment  for  12  of  the  patients,  ten  of  whom  discontinued
reatment.
Disease  progression  was  documented  for  70  patients
60.9%).  Median  PFS  was  165  days  {CI95%:  83.3--246.7},
quivalent  to  5.4  months.  The  proportion  of  patients  who
ere  progression  free  at  one-year  was  36%.
rimary  outcomes
rom  the  115  patients  that  started  treatment  with
ivolumab,  56  have  died  (48.7%).  Median  OS  considering  this
ntire  sample  was  11.4  months  with  a  one-year  OS  of  44%.
he  confidence  interval  for  the  median  OS  was  not  possible
o  estimate.
Restricting  the  analysis  to  patients  with  non-squamous
arcinomas  (n  =  107),  for  purposes  of  comparison  with  the
linical  trials  leading  to  drug  approval,  there  were  53  deaths
49.5%).  Median  OS  in  this  subgroup  was  the  same,  11.4
onths,  also  with  the  same  one-year  OS,  44%  (Fig.  1).
Median  PFS  in  the  overall  sample  (n  =  115)  was  5.4  months
CI95%: 2.7--8.1}, slightly  reduced  when  considering  the  non-
quamous  subgroup  (n  =  107)  to  5.3  months  {CI95%:  2.8--7.9}.
ne-year  PFS  for  the  non-squamous  subgroup  was  36%.  In
able  2,  the  comparison  of  treatment  response  is  made
nder  comparable  conditions  to  the  clinical  trial,  i.e.,  only
onsidering  non-squamous  carcinomas  (n  =  107)  and  in  the
ase  of  therapeutic  response  evaluation,  only  considering
hose  treated  for  9  weeks  or  over  (n  =  76),  a  note  also  indi-
ated  in  the  table  footer  (Table  2).
6  F.A.  Costa  et  al.
Table  1  Causes  of  treatment  interruption  and  distribution
of adverse  drug  reactions.
Adverse  effects  leading  to
treatment  interruption
Disease  progression  40
Adverse  drug  reactions  20
Death 12
Patient refusal  2
Detection  of  progression  of  another  tumour  1
Hospitalisation  for  other  reasons  1
Unknown  6
Total 82




Pneumonitis  4  7
Hypothyroidism  0  6
Shortness  of  breath  and
respiratory  problems
3  4
Gastrointestinal  toxicity  2  3
Hematologic  toxicity  2  2
Weakness  and  asthenia  2  2
Metabolic  acidosis  2  2
Cutaneous  toxicity  1  2
Diarrhoea  1  1
Macular  rash 0  1
Hepatic  toxicity  1  1
Neurologic  toxicity  1  1
Hyperthyroidism  1  1
Diabetes  0  1
Pneumothorax  0  1
Deep vein  thrombosis 0  1

































Figure  1  Overall  survival  observed  in  the  cohort  of  non-
squamous  lung  cancer  patients  (n  =  107)  cumulative  survival.
Table  2  Comparison  of  clinical  trial  data  with  real-world
effectiveness  data.
Real  world  data
(n  =  107)
Clinical  trial  data6




65  {37--83}  61  {37--84}
≥75  years  13  (12.1%)  20  (7.0%)
Previous  chemotherapy
One  regimen  34  (29.6%)  256  (88.0%)
Two regimens 41  (35.6%) 35  (12.0%)
Three  or  more
regimensa




38  (35.5%)  199  (69.0%)
Therapeutic  response  (n  =  76)b
Complete
response
1  (1.3%)  4  (1.0%)
Partial  response 14  (18.4%) 52  (18.0%)
Stable  disease 37  (48.7%) 74  (25.0%)
Disease
progression
18 (23.7%) 129  (44.0%)
Not evaluated  6  (7.9%)  33  (11.0%)















1-year  OS  44.0%  51.0%  {45.0--56.0}


















b Therapeutic response was compared considering only those
patients treated for 9 weeks or longer, as reported elsewhere.6
iscussion
he  clinical  outcomes  that  were  observed  in  this  cohort  of
atients  with  NSCLC  treated  with  nivolumab  were  similar
o  those  reported  in  the  clinical  trial  which  had  led  to  its
pproval  in  non-squamous  NSCLC  patients.6 The  median  OS
bserved  in  real  world  data  was  11.4  months,  slightly  infe-
ior  to  the  12.2  months  reported  in  the  clinical  trial  but
till  superior  to  the  9.4  months  reported  for  treatment  with
ocetaxel.  Worth  mentioning,  we  presume  that  the  median
S  with  docetaxel  in  real  world  data  would  most  likely  be
horter.  Furthermore,  the  characteristics  of  patients  receiv-
ng  nivolumab  indicate  they  had  worse  prognostic  factors,
ith  a  higher  proportion  of  patients  both  older  than  75  years
nd  having  undergone  three  or  more  lines  of  chemotherapy
rior  to  treatment  with  nivolumab.It is  worth  noting  that  although  the  observed  OS  was
lightly  inferior  to  that  reported  in  the  clinical  trial,  the  PFS





























The  cancer  registry  as  an  ally  in  monitoring  treatment  effec
is  that  in  clinical  trials,  patients  are  more  frequently  subject
to  CTs,  hence  progressions  are  detected  earlier.  In  real  life,
CTs  are  often  delayed  by  waiting  times  associated  with  an
overloaded  healthcare  system.  PFS  at  one-year  was  higher
than  in  the  clinical  trial  (36.0%  versus  19.0%).6 This  find-
ing  seems  surprising  and  we  believe  it  could  be  a  result  of
some  study  limitations,  namely  the  fact  that  considering  dis-
ease  progression  could  be  a  result  of  observed  computerised
tomographies  (CTs),  but  also  of  clinical  judgement;  also,  in
real  life  various  oncologists  judge  disease  progression,  which
could  lead  to  misclassification  bias.
We  have  demonstrated  that  the  cancer  Registry  database
may  be  successfully  used  to  monitor  treatment  outcomes,
although  a  great  effort  needs  to  be  placed  on  ensuring  the
exhaustiveness  of  registered  data.
The  main  limitation  of  this  study  is  the  scant  informa-
tion  on  patients  treated  in  central  and  north  regions.  The
new  legislation  for  the  National  Oncology  Registry8 which
anticipates  mandatory  registration  of  cases,  as  opposed  to
the  voluntary  registration  observed  at  the  regional  level
observed  since  1988,11 will  certainly  be  fundamental  in  over-
coming  this  problem.  As  a  consequence  of  this  limitation,
the  sample  is  smaller  than  ideal,  limiting  our  capacity  to
undertake  potentially  interesting  sub-analysis.  For  example,
it  could  have  been  useful  to  compare  OS  of  patients  under-
going  nivolumab  as  second  line  treatment  compared  to  those
exposed  as  third,  fourth  or  even  fifth  line  of  treatment.
The  other  limitations  of  this  study  derived  from
sometimes  insufficient  information  in  medical  records.
Oncologists  involved  in  the  study  had  a  determinant  role  in
this  aspect.  A  great  effort  was  made  to  motivate  colleagues
to  document  in  detail  all  aspects  of  treatment.  Tradition-
ally,  physicians  focus  on  delivering  clinical  care  and,  due  to
time  constraints  inherent  to  the  health  system  structure  and
its  demands,  minimise  documentation  in  patient  medical
records.  As  a  result,  some  variables  are  more  often  detailed
than  others.  Tumour  characterisation  is  one  example  of  a
set  of  variables  where  accuracy  is  extremely  high.  In  con-
trast,  outside  clinical  trials,  treatment  characterisation  is
less  detailed.  There  needs  to  be  a  change  in  mentality  and
work  organisation  in  this  new  era  of  real  life  data  collection
and  analysis.  Treatment  must  be  seen  as  an  essential  compo-
nent  of  the  registry.  To  fully  characterise  drug  exposure,  it  is
of  utmost  importance  to  know  the  treatment  duration,  dose
delivered,  adverse  drug  reactions  observed  and  response  to
treatment.
The  proportion  of  ADRs  reported  was  low.  This  is  prob-
ably  a  result  of  under  registration  rather  than  extreme
safety  of  nivolumab.  Therefore,  results  need  to  be  inter-
preted  with  caution.  Among  registered  ADRs,  grades  were
very  seldom  documented,  supporting  the  previous  assump-
tion.  We  are  currently  working  in  the  cancer  registry
on  upgrading  the  fields  for  monitoring  ADRs  to  enable
the  quantification  of  grades  and  also  to  document  all
observed  ADRs  and  not  merely  the  ones  leading  to
treatment  discontinuation.  This  is  particularly  important
because  most  of  these  drugs  are  subject  to  additional
monitoring  according  to  the  pharmacovigilance  European
legislation.
To  the  best  of  our  knowledge,  this  is  the  first  national
study  to  show  that  a  population-based  cancer  registry  can
be  used  to  monitor  the  effectiveness  of  new  treatments,ess  7
roviding  valuable  evidence  for  policy  makers  to  base  reim-
ursement  decisions.  In  the  future,  data  may  be  used  to
etermine  full  or  partial  reimbursement  according  to  results
rom  different  effectiveness  profiles.  As  an  example,  our
ata  suggests  that  the  benefit  obtained  using  nivolumab
n  non-squamous  cell  lung  cancers  is  substantially  higher
han  the  benefit  obtained  in  squamous  cell  cancer  (data  not
hown).  Although  this  result  should  be  interpreted  with  cau-
ion  due  to  the  limited  sample  size  of  the  squamous  group,
he  finding  is  supported  by  the  published  clinical  trial  data.
onclusion
he  cancer  registry  is  a  powerful  source  of  data  to  monitor
he  treatment  of  cancer,  provided  education,  training  and,
erhaps,  incentives  are  used  to  change  the  mentality  and
he  work  organisation  so  that  complete  treatment  data  is
ollected  routinely.
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